Nuzee [NUZE] - Last Close: $0.7828
Nuzee is still running hot after a big announcement on Wednesday.
Yesterday, the food products company announced a collaboration to produce sustainable packaging for Malu's single-serve specialty coffee line.
Nuzee initially gained 54.4% in response to the news, and it's adding to its lead in today's premarket.
The stock is running hot with a 20.3% gain this morning, enough to make it one of the morning's top performers.
My Take: NUZE still has momentum despite chalking up big gains yesterday. The real question is whether it can hang onto those leads through to today's close. Watch for a potential pullback at the opening bell.
Nogin [NOGN] - Last Close: $0.80
Nogin is trending after announcing results to a recently-conducted survey.
The eCommerce tech firm announced a survey of D2C brands found companies are seeking to beef up their platforms and tech stacks this year.
Nogin's survey found D2C brands also want to explore better solutions to future-proof their businesses, and create next-gen eCommerce platforms.
The survey results could be a favorable sign for Nogin, which specializes in the type of high-tech solutions many respondents said they needed.
NOGN is one of this morning's top performers with a 22.5% gain after unveiling the results of its D2C survey on Wednesday.
My Take: NOGN only gained 1.5% after the news hit the market on Wednesday, so I am not sure why we're seeing such a delayed reaction. There's no other recent news to explain the move, and the stock has a modest short ratio of 1.99%.
XORTX Therapeutics [XRTX] - Last Close: $0.7828
Promising clinical date is boosting shares of XORTX Therapeutics.
The biopharma firm announced positive results from the XEX-OXY-101 Bridging Pharmacokinetics Trial evaluating Xorlo to treat progressive kidney disease.
Xorlo was well tolerated across various dosing regimens, and no safety issues were identified in any of trail's four phases.
The trial also provided data that will help the company facilitate precise dosing recommendations for the upcoming Phase 3 registration trial.
The early morning announcement of the drug's strong clinical performance sent XRTX to a 83.9% gain on active trading volume in today's premarket.
My Take: This clinical data looks promising, and it could be an indicator of more clinical catalysts to come in this stock's near future.
Starbox Holdings [STBX] - Last Close: $3.03
Upbeat earnings results are lifting shares of Starbox Holdings this morning.
The Malaysia-based digital ad firm announced its fiscal 2022 results after Wednesday's closing bell, and the market liked the numbers.
Starbox posted annual 127.2% revenue growth for the year, along with a net income increase of 148.8%.
The company also noted substantial operational improvements, including increases in the number of merchants, members, and transactions.
Starbox's strong growth numbers got investors' attention, and its shares are up 22.1% in today's premarket in response to the announcement.
My Take: Starbox's numbers look great, and share prices have been trending higher since late December. This stock could be on the up and up.
